Podcast appearances and mentions of Roy F Chemaly

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/WAV865. CME/NCPD credit will be available until March 25, 2025.Cracking Down on Post-Transplant CMV: Guidance on Sequential Treatment With Newer Antiviral AgentsThe Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education. In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/WAV865. CME/NCPD credit will be available until March 25, 2025.Cracking Down on Post-Transplant CMV: Guidance on Sequential Treatment With Newer Antiviral AgentsThe Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education. In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/WAV865. CME/NCPD credit will be available until March 25, 2025.Cracking Down on Post-Transplant CMV: Guidance on Sequential Treatment With Newer Antiviral AgentsThe Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education. In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/WAV865. CME/NCPD credit will be available until March 25, 2025.Cracking Down on Post-Transplant CMV: Guidance on Sequential Treatment With Newer Antiviral AgentsThe Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education. In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/WAV865. CME/NCPD credit will be available until March 25, 2025.Cracking Down on Post-Transplant CMV: Guidance on Sequential Treatment With Newer Antiviral AgentsThe Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education. In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/WAV865. CME/NCPD credit will be available until March 25, 2025.Cracking Down on Post-Transplant CMV: Guidance on Sequential Treatment With Newer Antiviral AgentsThe Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education. In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/WAV865. CME/NCPD credit will be available until March 25, 2025.Cracking Down on Post-Transplant CMV: Guidance on Sequential Treatment With Newer Antiviral AgentsThe Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education. In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/WAV865. CME/NCPD credit will be available until March 25, 2025.Cracking Down on Post-Transplant CMV: Guidance on Sequential Treatment With Newer Antiviral AgentsThe Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education. In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.Disclosure information is available at the beginning of the video presentation.

Go online to PeerView.com/ZXF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cytomegalovirus (CMV) is a leading opportunistic infection in immunocompromised patients, including allogeneic hematopoietic stem cell transplant (HCT) recipients, where primary infection or reactivation is associated with increased morbidity and mortality. Antiviral drugs are the mainstay for the prevention of CMV infection and disease, most commonly with valganciclovir. However, valganciclovir use is often associated with adverse drug reactions, most notably leukopenia and neutropenia, and its widespread use has led to the emergence of antiviral resistance. Foscarnet and cidofovir, however, are associated with nephrotoxicity. After many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. Indeed, letermovir was recently approved for CMV prophylaxis in allogeneic HCT recipients, and data suggest that maribavir has the potential to address the unmet need of treating relapsed or resistant CMV infections. In this activity, based on a live symposium, experts offer insight into managing CMV in HCT recipients in a new era of antiviral therapy. Foundational guidance is combined with a discussion of real cases. Hear about best practices in preventing CMV infection in patients undergoing HCT, as well as the potential role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Discuss the burden of cytomegalovirus (CMV) infection among hematopoietic stem cell transplant (HCT) recipients, Assess the latest clinical trial data regarding novel strategies to prevent and treat CMV infection in the HCT setting, Employ strategies to prevent and treat CMV infection in individual HCT recipients, considering current evidence, expert recommendations, and clinical trial enrollment for appropriate patients.

Go online to PeerView.com/ZXF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cytomegalovirus (CMV) is a leading opportunistic infection in immunocompromised patients, including allogeneic hematopoietic stem cell transplant (HCT) recipients, where primary infection or reactivation is associated with increased morbidity and mortality. Antiviral drugs are the mainstay for the prevention of CMV infection and disease, most commonly with valganciclovir. However, valganciclovir use is often associated with adverse drug reactions, most notably leukopenia and neutropenia, and its widespread use has led to the emergence of antiviral resistance. Foscarnet and cidofovir, however, are associated with nephrotoxicity. After many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. Indeed, letermovir was recently approved for CMV prophylaxis in allogeneic HCT recipients, and data suggest that maribavir has the potential to address the unmet need of treating relapsed or resistant CMV infections. In this activity, based on a live symposium, experts offer insight into managing CMV in HCT recipients in a new era of antiviral therapy. Foundational guidance is combined with a discussion of real cases. Hear about best practices in preventing CMV infection in patients undergoing HCT, as well as the potential role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Discuss the burden of cytomegalovirus (CMV) infection among hematopoietic stem cell transplant (HCT) recipients, Assess the latest clinical trial data regarding novel strategies to prevent and treat CMV infection in the HCT setting, Employ strategies to prevent and treat CMV infection in individual HCT recipients, considering current evidence, expert recommendations, and clinical trial enrollment for appropriate patients.

Go online to PeerView.com/ZXF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cytomegalovirus (CMV) is a leading opportunistic infection in immunocompromised patients, including allogeneic hematopoietic stem cell transplant (HCT) recipients, where primary infection or reactivation is associated with increased morbidity and mortality. Antiviral drugs are the mainstay for the prevention of CMV infection and disease, most commonly with valganciclovir. However, valganciclovir use is often associated with adverse drug reactions, most notably leukopenia and neutropenia, and its widespread use has led to the emergence of antiviral resistance. Foscarnet and cidofovir, however, are associated with nephrotoxicity. After many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. Indeed, letermovir was recently approved for CMV prophylaxis in allogeneic HCT recipients, and data suggest that maribavir has the potential to address the unmet need of treating relapsed or resistant CMV infections. In this activity, based on a live symposium, experts offer insight into managing CMV in HCT recipients in a new era of antiviral therapy. Foundational guidance is combined with a discussion of real cases. Hear about best practices in preventing CMV infection in patients undergoing HCT, as well as the potential role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Discuss the burden of cytomegalovirus (CMV) infection among hematopoietic stem cell transplant (HCT) recipients, Assess the latest clinical trial data regarding novel strategies to prevent and treat CMV infection in the HCT setting, Employ strategies to prevent and treat CMV infection in individual HCT recipients, considering current evidence, expert recommendations, and clinical trial enrollment for appropriate patients.

Go online to PeerView.com/ZXF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cytomegalovirus (CMV) is a leading opportunistic infection in immunocompromised patients, including allogeneic hematopoietic stem cell transplant (HCT) recipients, where primary infection or reactivation is associated with increased morbidity and mortality. Antiviral drugs are the mainstay for the prevention of CMV infection and disease, most commonly with valganciclovir. However, valganciclovir use is often associated with adverse drug reactions, most notably leukopenia and neutropenia, and its widespread use has led to the emergence of antiviral resistance. Foscarnet and cidofovir, however, are associated with nephrotoxicity. After many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. Indeed, letermovir was recently approved for CMV prophylaxis in allogeneic HCT recipients, and data suggest that maribavir has the potential to address the unmet need of treating relapsed or resistant CMV infections. In this activity, based on a live symposium, experts offer insight into managing CMV in HCT recipients in a new era of antiviral therapy. Foundational guidance is combined with a discussion of real cases. Hear about best practices in preventing CMV infection in patients undergoing HCT, as well as the potential role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Discuss the burden of cytomegalovirus (CMV) infection among hematopoietic stem cell transplant (HCT) recipients, Assess the latest clinical trial data regarding novel strategies to prevent and treat CMV infection in the HCT setting, Employ strategies to prevent and treat CMV infection in individual HCT recipients, considering current evidence, expert recommendations, and clinical trial enrollment for appropriate patients.

Go online to PeerView.com/ZXF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cytomegalovirus (CMV) is a leading opportunistic infection in immunocompromised patients, including allogeneic hematopoietic stem cell transplant (HCT) recipients, where primary infection or reactivation is associated with increased morbidity and mortality. Antiviral drugs are the mainstay for the prevention of CMV infection and disease, most commonly with valganciclovir. However, valganciclovir use is often associated with adverse drug reactions, most notably leukopenia and neutropenia, and its widespread use has led to the emergence of antiviral resistance. Foscarnet and cidofovir, however, are associated with nephrotoxicity. After many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. Indeed, letermovir was recently approved for CMV prophylaxis in allogeneic HCT recipients, and data suggest that maribavir has the potential to address the unmet need of treating relapsed or resistant CMV infections. In this activity, based on a live symposium, experts offer insight into managing CMV in HCT recipients in a new era of antiviral therapy. Foundational guidance is combined with a discussion of real cases. Hear about best practices in preventing CMV infection in patients undergoing HCT, as well as the potential role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Discuss the burden of cytomegalovirus (CMV) infection among hematopoietic stem cell transplant (HCT) recipients, Assess the latest clinical trial data regarding novel strategies to prevent and treat CMV infection in the HCT setting, Employ strategies to prevent and treat CMV infection in individual HCT recipients, considering current evidence, expert recommendations, and clinical trial enrollment for appropriate patients.

Go online to PeerView.com/ZXF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cytomegalovirus (CMV) is a leading opportunistic infection in immunocompromised patients, including allogeneic hematopoietic stem cell transplant (HCT) recipients, where primary infection or reactivation is associated with increased morbidity and mortality. Antiviral drugs are the mainstay for the prevention of CMV infection and disease, most commonly with valganciclovir. However, valganciclovir use is often associated with adverse drug reactions, most notably leukopenia and neutropenia, and its widespread use has led to the emergence of antiviral resistance. Foscarnet and cidofovir, however, are associated with nephrotoxicity. After many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. Indeed, letermovir was recently approved for CMV prophylaxis in allogeneic HCT recipients, and data suggest that maribavir has the potential to address the unmet need of treating relapsed or resistant CMV infections. In this activity, based on a live symposium, experts offer insight into managing CMV in HCT recipients in a new era of antiviral therapy. Foundational guidance is combined with a discussion of real cases. Hear about best practices in preventing CMV infection in patients undergoing HCT, as well as the potential role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Discuss the burden of cytomegalovirus (CMV) infection among hematopoietic stem cell transplant (HCT) recipients, Assess the latest clinical trial data regarding novel strategies to prevent and treat CMV infection in the HCT setting, Employ strategies to prevent and treat CMV infection in individual HCT recipients, considering current evidence, expert recommendations, and clinical trial enrollment for appropriate patients.

Go online to PeerView.com/ZXF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cytomegalovirus (CMV) is a leading opportunistic infection in immunocompromised patients, including allogeneic hematopoietic stem cell transplant (HCT) recipients, where primary infection or reactivation is associated with increased morbidity and mortality. Antiviral drugs are the mainstay for the prevention of CMV infection and disease, most commonly with valganciclovir. However, valganciclovir use is often associated with adverse drug reactions, most notably leukopenia and neutropenia, and its widespread use has led to the emergence of antiviral resistance. Foscarnet and cidofovir, however, are associated with nephrotoxicity. After many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. Indeed, letermovir was recently approved for CMV prophylaxis in allogeneic HCT recipients, and data suggest that maribavir has the potential to address the unmet need of treating relapsed or resistant CMV infections. In this activity, based on a live symposium, experts offer insight into managing CMV in HCT recipients in a new era of antiviral therapy. Foundational guidance is combined with a discussion of real cases. Hear about best practices in preventing CMV infection in patients undergoing HCT, as well as the potential role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Discuss the burden of cytomegalovirus (CMV) infection among hematopoietic stem cell transplant (HCT) recipients, Assess the latest clinical trial data regarding novel strategies to prevent and treat CMV infection in the HCT setting, Employ strategies to prevent and treat CMV infection in individual HCT recipients, considering current evidence, expert recommendations, and clinical trial enrollment for appropriate patients.

Go online to PeerView.com/ZXF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cytomegalovirus (CMV) is a leading opportunistic infection in immunocompromised patients, including allogeneic hematopoietic stem cell transplant (HCT) recipients, where primary infection or reactivation is associated with increased morbidity and mortality. Antiviral drugs are the mainstay for the prevention of CMV infection and disease, most commonly with valganciclovir. However, valganciclovir use is often associated with adverse drug reactions, most notably leukopenia and neutropenia, and its widespread use has led to the emergence of antiviral resistance. Foscarnet and cidofovir, however, are associated with nephrotoxicity. After many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. Indeed, letermovir was recently approved for CMV prophylaxis in allogeneic HCT recipients, and data suggest that maribavir has the potential to address the unmet need of treating relapsed or resistant CMV infections. In this activity, based on a live symposium, experts offer insight into managing CMV in HCT recipients in a new era of antiviral therapy. Foundational guidance is combined with a discussion of real cases. Hear about best practices in preventing CMV infection in patients undergoing HCT, as well as the potential role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Discuss the burden of cytomegalovirus (CMV) infection among hematopoietic stem cell transplant (HCT) recipients, Assess the latest clinical trial data regarding novel strategies to prevent and treat CMV infection in the HCT setting, Employ strategies to prevent and treat CMV infection in individual HCT recipients, considering current evidence, expert recommendations, and clinical trial enrollment for appropriate patients.

Go online to PeerView.com/JVG860 to view the entire program with slides. Effective antiviral prophylaxis and therapy for opportunistic human cytomegalovirus (CMV) infection in transplant recipients and other immunocompromised hosts has long relied mainly on ganciclovir and its oral prodrug valganciclovir, with foscarnet and cidofovir in secondary roles. Use of these viral DNA polymerase inhibitors has improved clinical outcomes, particularly when used as prophylaxis or preventive therapy, but their use is associated with well-known limitations of toxicity as well as cross-resistance due to the same antiviral drug target. However, after many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts discuss managing CMV in hematopoietic cell transplant (HCT) recipients in a new era of antiviral therapy. Utilizing interactive clinical case scenarios, the expert faculty outlines best practices to prevent CMV infection in patients undergoing HCT and then examine the role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Identify unmet needs associated with the management of CMV infection in HCT recipients, Describe the efficacy and safety of novel strategies to prevent and treat CMV infection in the HCT setting, Integrate expert recommendations and recent evidence into the therapeutic decision-making process to prevent and treat CMV infection after HCT.

Go online to PeerView.com/JVG860 to view the entire program with slides. Effective antiviral prophylaxis and therapy for opportunistic human cytomegalovirus (CMV) infection in transplant recipients and other immunocompromised hosts has long relied mainly on ganciclovir and its oral prodrug valganciclovir, with foscarnet and cidofovir in secondary roles. Use of these viral DNA polymerase inhibitors has improved clinical outcomes, particularly when used as prophylaxis or preventive therapy, but their use is associated with well-known limitations of toxicity as well as cross-resistance due to the same antiviral drug target. However, after many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts discuss managing CMV in hematopoietic cell transplant (HCT) recipients in a new era of antiviral therapy. Utilizing interactive clinical case scenarios, the expert faculty outlines best practices to prevent CMV infection in patients undergoing HCT and then examine the role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Identify unmet needs associated with the management of CMV infection in HCT recipients, Describe the efficacy and safety of novel strategies to prevent and treat CMV infection in the HCT setting, Integrate expert recommendations and recent evidence into the therapeutic decision-making process to prevent and treat CMV infection after HCT.

Go online to PeerView.com/JVG860 to view the entire program with slides. Effective antiviral prophylaxis and therapy for opportunistic human cytomegalovirus (CMV) infection in transplant recipients and other immunocompromised hosts has long relied mainly on ganciclovir and its oral prodrug valganciclovir, with foscarnet and cidofovir in secondary roles. Use of these viral DNA polymerase inhibitors has improved clinical outcomes, particularly when used as prophylaxis or preventive therapy, but their use is associated with well-known limitations of toxicity as well as cross-resistance due to the same antiviral drug target. However, after many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts discuss managing CMV in hematopoietic cell transplant (HCT) recipients in a new era of antiviral therapy. Utilizing interactive clinical case scenarios, the expert faculty outlines best practices to prevent CMV infection in patients undergoing HCT and then examine the role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Identify unmet needs associated with the management of CMV infection in HCT recipients, Describe the efficacy and safety of novel strategies to prevent and treat CMV infection in the HCT setting, Integrate expert recommendations and recent evidence into the therapeutic decision-making process to prevent and treat CMV infection after HCT.

Go online to PeerView.com/JVG860 to view the entire program with slides. Effective antiviral prophylaxis and therapy for opportunistic human cytomegalovirus (CMV) infection in transplant recipients and other immunocompromised hosts has long relied mainly on ganciclovir and its oral prodrug valganciclovir, with foscarnet and cidofovir in secondary roles. Use of these viral DNA polymerase inhibitors has improved clinical outcomes, particularly when used as prophylaxis or preventive therapy, but their use is associated with well-known limitations of toxicity as well as cross-resistance due to the same antiviral drug target. However, after many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts discuss managing CMV in hematopoietic cell transplant (HCT) recipients in a new era of antiviral therapy. Utilizing interactive clinical case scenarios, the expert faculty outlines best practices to prevent CMV infection in patients undergoing HCT and then examine the role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Identify unmet needs associated with the management of CMV infection in HCT recipients, Describe the efficacy and safety of novel strategies to prevent and treat CMV infection in the HCT setting, Integrate expert recommendations and recent evidence into the therapeutic decision-making process to prevent and treat CMV infection after HCT.

Go online to PeerView.com/JVG860 to view the entire program with slides. Effective antiviral prophylaxis and therapy for opportunistic human cytomegalovirus (CMV) infection in transplant recipients and other immunocompromised hosts has long relied mainly on ganciclovir and its oral prodrug valganciclovir, with foscarnet and cidofovir in secondary roles. Use of these viral DNA polymerase inhibitors has improved clinical outcomes, particularly when used as prophylaxis or preventive therapy, but their use is associated with well-known limitations of toxicity as well as cross-resistance due to the same antiviral drug target. However, after many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts discuss managing CMV in hematopoietic cell transplant (HCT) recipients in a new era of antiviral therapy. Utilizing interactive clinical case scenarios, the expert faculty outlines best practices to prevent CMV infection in patients undergoing HCT and then examine the role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Identify unmet needs associated with the management of CMV infection in HCT recipients, Describe the efficacy and safety of novel strategies to prevent and treat CMV infection in the HCT setting, Integrate expert recommendations and recent evidence into the therapeutic decision-making process to prevent and treat CMV infection after HCT.

Go online to PeerView.com/JVG860 to view the entire program with slides. Effective antiviral prophylaxis and therapy for opportunistic human cytomegalovirus (CMV) infection in transplant recipients and other immunocompromised hosts has long relied mainly on ganciclovir and its oral prodrug valganciclovir, with foscarnet and cidofovir in secondary roles. Use of these viral DNA polymerase inhibitors has improved clinical outcomes, particularly when used as prophylaxis or preventive therapy, but their use is associated with well-known limitations of toxicity as well as cross-resistance due to the same antiviral drug target. However, after many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts discuss managing CMV in hematopoietic cell transplant (HCT) recipients in a new era of antiviral therapy. Utilizing interactive clinical case scenarios, the expert faculty outlines best practices to prevent CMV infection in patients undergoing HCT and then examine the role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Identify unmet needs associated with the management of CMV infection in HCT recipients, Describe the efficacy and safety of novel strategies to prevent and treat CMV infection in the HCT setting, Integrate expert recommendations and recent evidence into the therapeutic decision-making process to prevent and treat CMV infection after HCT.

Go online to PeerView.com/JVG860 to view the entire program with slides. Effective antiviral prophylaxis and therapy for opportunistic human cytomegalovirus (CMV) infection in transplant recipients and other immunocompromised hosts has long relied mainly on ganciclovir and its oral prodrug valganciclovir, with foscarnet and cidofovir in secondary roles. Use of these viral DNA polymerase inhibitors has improved clinical outcomes, particularly when used as prophylaxis or preventive therapy, but their use is associated with well-known limitations of toxicity as well as cross-resistance due to the same antiviral drug target. However, after many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts discuss managing CMV in hematopoietic cell transplant (HCT) recipients in a new era of antiviral therapy. Utilizing interactive clinical case scenarios, the expert faculty outlines best practices to prevent CMV infection in patients undergoing HCT and then examine the role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Identify unmet needs associated with the management of CMV infection in HCT recipients, Describe the efficacy and safety of novel strategies to prevent and treat CMV infection in the HCT setting, Integrate expert recommendations and recent evidence into the therapeutic decision-making process to prevent and treat CMV infection after HCT.

Go online to PeerView.com/JVG860 to view the entire program with slides. Effective antiviral prophylaxis and therapy for opportunistic human cytomegalovirus (CMV) infection in transplant recipients and other immunocompromised hosts has long relied mainly on ganciclovir and its oral prodrug valganciclovir, with foscarnet and cidofovir in secondary roles. Use of these viral DNA polymerase inhibitors has improved clinical outcomes, particularly when used as prophylaxis or preventive therapy, but their use is associated with well-known limitations of toxicity as well as cross-resistance due to the same antiviral drug target. However, after many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts discuss managing CMV in hematopoietic cell transplant (HCT) recipients in a new era of antiviral therapy. Utilizing interactive clinical case scenarios, the expert faculty outlines best practices to prevent CMV infection in patients undergoing HCT and then examine the role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Identify unmet needs associated with the management of CMV infection in HCT recipients, Describe the efficacy and safety of novel strategies to prevent and treat CMV infection in the HCT setting, Integrate expert recommendations and recent evidence into the therapeutic decision-making process to prevent and treat CMV infection after HCT.

Go online to PeerView.com/JVG860 to view the entire program with slides. Effective antiviral prophylaxis and therapy for opportunistic human cytomegalovirus (CMV) infection in transplant recipients and other immunocompromised hosts has long relied mainly on ganciclovir and its oral prodrug valganciclovir, with foscarnet and cidofovir in secondary roles. Use of these viral DNA polymerase inhibitors has improved clinical outcomes, particularly when used as prophylaxis or preventive therapy, but their use is associated with well-known limitations of toxicity as well as cross-resistance due to the same antiviral drug target. However, after many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts discuss managing CMV in hematopoietic cell transplant (HCT) recipients in a new era of antiviral therapy. Utilizing interactive clinical case scenarios, the expert faculty outlines best practices to prevent CMV infection in patients undergoing HCT and then examine the role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Identify unmet needs associated with the management of CMV infection in HCT recipients, Describe the efficacy and safety of novel strategies to prevent and treat CMV infection in the HCT setting, Integrate expert recommendations and recent evidence into the therapeutic decision-making process to prevent and treat CMV infection after HCT.

Go online to PeerView.com/JVG860 to view the entire program with slides. Effective antiviral prophylaxis and therapy for opportunistic human cytomegalovirus (CMV) infection in transplant recipients and other immunocompromised hosts has long relied mainly on ganciclovir and its oral prodrug valganciclovir, with foscarnet and cidofovir in secondary roles. Use of these viral DNA polymerase inhibitors has improved clinical outcomes, particularly when used as prophylaxis or preventive therapy, but their use is associated with well-known limitations of toxicity as well as cross-resistance due to the same antiviral drug target. However, after many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts discuss managing CMV in hematopoietic cell transplant (HCT) recipients in a new era of antiviral therapy. Utilizing interactive clinical case scenarios, the expert faculty outlines best practices to prevent CMV infection in patients undergoing HCT and then examine the role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Identify unmet needs associated with the management of CMV infection in HCT recipients, Describe the efficacy and safety of novel strategies to prevent and treat CMV infection in the HCT setting, Integrate expert recommendations and recent evidence into the therapeutic decision-making process to prevent and treat CMV infection after HCT.